Table 3. Cox Proportional Hazards Regression Models of Risk Factors Associated with Recurrece-free Survival.
| Recurrence-free survival | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Univariate analysis* | Multivariate analysis | Multivariate analysis* | |||||||||
| HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
| Age (≥60 vs. <60) | 1.30 | [0.71, 2.40] | 0.392 | 1.46 | [0.79, 2.69] | 0.230 | ||||||
| BMI (kg/m2) | 1.06 | [0.91, 1.23] | 0.474 | 1.07 | [0.91, 1.25] | 0.436 | ||||||
| Histology (non-squamous vs. squamous) | 2.08 | [1.21, 3.58] | 0.008 | 2.17 | [1.24, 3.79] | 0.007 | — | — | — | — | — | — |
| Tumor stage (IIA2 vs IB2) | 0.92 | [0.57, 1.50] | 0.737 | 1.09 | [0.85, 1.40] | 0.512 | ||||||
| Tumor differentiation (G3 vs. G1-2) | 0.66 | [0.29, 1.53] | 0.336 | 0.74 | [0.32, 1.72] | 0.488 | ||||||
| Deep stromal invasion (yes vs. no) | 2.25 | [0.97, 5.21] | 0.059 | 2.57 | [1.03, 6.42] | 0.043 | — | — | — | |||
| LVSI (yes vs. no) | 1.91 | [1.11, 3.28] | 0.020 | 2.01 | [1.14, 3.56] | 0.016 | — | — | — | — | — | — |
| Positive margins (yes vs. no) | 10.70 | [5.76, 19.89] | <0.0001 | 10.37 | [5.45, 19.75] | <0.0001 | 4.80 | [2.51, 9.18] | <0.0001 | 4.95 | [2.50, 9.80] | <0.0001 |
| Positive nodes (yes vs. no) | 7.06 | [3.84, 12.98] | <0.0001 | 7.17 | [3.81, 13.49] | <0.0001 | 4.54 | [2.42, 8.52] | <0.0001 | 4.42 | [2.30, 8.48] | <0.0001 |
| Positive parametrium (yes vs. no) | 8.16 | [4.33, 15.39] | <0.0001 | 7.81 | [4.04, 15.13] | <0.0001 | 3.13 | [1.61, 6.06] | 0.001 | 3.12 | [1.55, 6.28] | 0.001 |
| Adjuvant chemotherapy (yes vs. no) | 0.79 | [0.43, 1.45] | 0.451 | 0.68 | [0.35, 1.31] | 0.248 | ||||||
| CR achieved (yes vs. no) | 0.08 | [0.02, 0.34] | 0.001 | 0.09 | [0.02, 0.35] | 0.001 | 0.18 | [0.04, 0.77] | 0.020 | 0.18 | [0.04, 0.74] | 0.018 |
| FBG (>100 mg/dl vs <100 mg/dl) | 1.95 | [1.16, 3.28] | 0.012 | 2.00 | [1.14, 3.50] | 0.015 | 1.69 | [1.00, 2.85] | 0.050 | — | — | — |
| CHO (≥200 mg/dl vs. <200 mg/dl) | 0.86 | [0.53, 1.41] | 0.560 | 0.84 | [0.51, 1.40] | 0.509 | ||||||
| TG (≥150 mg/dl vs. <150 mg/dl) | 0.89 | [0.47, 1.66] | 0.703 | 0.82 | [0.42, 1.62] | 0.575 | ||||||
| LDL-C (≥130 mg/dl vs. <130 mg/dl) | 0.70 | [0.34, 1.41] | 0.313 | 0.82 | [0.40, 1.66] | 0.574 | ||||||
| HDL-C (≥40 mg/dl vs. <40 mg/dl) | 1.45 | [0.66, 3.17] | 0.358 | 1.19 | [0.48, 2.96] | 0.713 | ||||||
| SCCA (≥3.5 mg/dl vs. <3.5 mg/dl) | 1.63 | [0.97, 2.73] | 0.067 | 1.60 | [0.93, 2.71] | 0.089 | ||||||
| Chemotherapy regimen (Cisplatin+paclitaxel vs. cisplatin-based) | 0.91 | [0.41, 1.96] | 0.805 | 0.99 | [0.45, 2.18] | 0.981 | ||||||
| CCRT (yes vs. no) | 4.10 | [1.29, 13.06] | 0.017 | 5.67 | [1.39, 23.21] | 0.016 | — | — | — | — | — | — |
* Patients with diabetes were excluded.
Abbreviation: BMI, body mass index; CCRT, cocurrent chemoradiotherapy; CI, confidence interval; CR, complete response; CHO, total cholesterol; DM, diabetes mellitus; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; LVSI, lymphatic vascular space involvement; NACT, neoadjuvant chemotherapy; SCCA, squamous cell carcinoma antigen; TG, triglyceride